search
Back to results

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (ARTISTRY-7)

Primary Purpose

Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Nemvaleukin and Pembrolizumab Combination
Pembrolizumab
Nemvaleukin
Pegylated Liposomal Doxorubicin (PLD)
Paclitaxel
Topotecan
Gemcitabine
Sponsored by
Alkermes, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Platinum-resistant Ovarian Cancer focused on measuring PROC, EOC, ALKS 4230, IL-2, Ovarian Cancer, KEYNOTE-C71, Platinum Resistant, Epithelian Ovarian Cancer, Nemvaleukin alfa, Pembrolizumab, ARTISTRY-7, ART-7, paclitaxel, pegylated liposoma doxorubicin, PLD, topotecan, gemzar, gemcitabine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient is female and ≥18 years of age.
  • Patient has histologically confirmed diagnosis of EOC (ie, high-grade serous, endometrioid of any grade, clear cell), fallopian tube cancer, or primary peritoneal cancer.
  • Patient has platinum-resistant/refractory disease, defined as disease progression within 180 days following the last administered dose of platinum therapy beyond first-line setting (resistant) or lack of response or disease progression while receiving the most recent platinum-based therapy (refractory). Patient must have progressed radiographically on or after their most recent line of anticancer therapy.
  • Patient must have received at least 1 prior line of systemic anticancer therapy in the platinum sensitive setting, and no more than 5 prior lines of systemic anticancer therapy in the platinum-resistant setting. Patient must have received at least 1 line of therapy containing bevacizumab.
  • Patient has at least one measurable lesion that qualifies as a target lesion based on RECISTv1.1.
  • Patient is willing to undergo a pre-treatment tumor biopsy or provide qualifying archival tumor tissue.

Exclusion Criteria:

  • Patient has primary platinum-refractory disease or primary platinum resistance, defined as disease progression during first-line platinum-based therapy (refractory) or disease progression <3 months after completion of first-line platinum-based therapy (resistant).
  • Patient has histologically confirmed diagnosis of EOC with mucinous or carcinosarcoma subtype.
  • Patient has nonepithelial tumor (eg, germline or stromal cell tumor) or ovarian tumor with low malignant potential (ie, borderline or low-grade serous tumor).
  • Patient requires fluid drainage (eg, paracentesis, thoracentesis, pericardiocentesis) of ≥500 mL within 6 weeks of first dose of study drug.
  • Patient has received prior IL-2-based or IL-15-based cytokine therapy; patient has had exposure, including intralesional, to IL-12 or analogs thereof.
  • Patient has prior exposure to any anti-PD1/PD-L1 therapy.

Sites / Locations

  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigational SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator Site
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes InvestigatorRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting
  • Alkermes Investigator SiteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Active Comparator

Arm Label

Nemvaleukin and Pembrolizumab Combination

Pembrolizumab

Nemvaleukin

Investigator's Choice

Arm Description

Options for protocol-specific Investigator's choice chemotherapy include one of the following: pegylated liposomal doxorubicin (PLD), paclitaxel, topotecan, or gemcitabine. The Investigator will pre-select the Investigator's choice treatment before the randomization of each patient.

Outcomes

Primary Outcome Measures

Progression-free survival (PFS) as assessed by Investigator

Secondary Outcome Measures

Objective response rate as assessed by Investigator
Overall Survival Rate
Disease Control Rate (DCR) as assessed by Investigator
Duration of Response (DOR) as assessed by Investigator
Time to Response (TTR) as assessed by Investigator
Cancer antigen (CA)-125 response as defined by the Gynecologic Cancer InterGroup (GCIG)
Incidence of treatment-emergent adverse events (TEAEs)

Full Information

First Posted
October 13, 2021
Last Updated
August 31, 2023
Sponsor
Alkermes, Inc.
Collaborators
Merck Sharp & Dohme LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT05092360
Brief Title
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
Acronym
ARTISTRY-7
Official Title
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 10, 2022 (Actual)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
December 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alkermes, Inc.
Collaborators
Merck Sharp & Dohme LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Detailed Description
Patients will be centrally allocated in a randomized fashion (3:1:1:3) to receive either: Arm 1: Nemvaleukin and pembrolizumab combination therapy Arm 2: Pembrolizumab monotherapy Arm 3: Nemvaleukin monotherapy Arm 4: Investigator's choice chemotherapy include one of the following: pegylated liposomal doxorubicin (PLD), paclitaxel, topotecan, or gemcitabine.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Keywords
PROC, EOC, ALKS 4230, IL-2, Ovarian Cancer, KEYNOTE-C71, Platinum Resistant, Epithelian Ovarian Cancer, Nemvaleukin alfa, Pembrolizumab, ARTISTRY-7, ART-7, paclitaxel, pegylated liposoma doxorubicin, PLD, topotecan, gemzar, gemcitabine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
376 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Nemvaleukin and Pembrolizumab Combination
Arm Type
Experimental
Arm Title
Pembrolizumab
Arm Type
Experimental
Arm Title
Nemvaleukin
Arm Type
Experimental
Arm Title
Investigator's Choice
Arm Type
Active Comparator
Arm Description
Options for protocol-specific Investigator's choice chemotherapy include one of the following: pegylated liposomal doxorubicin (PLD), paclitaxel, topotecan, or gemcitabine. The Investigator will pre-select the Investigator's choice treatment before the randomization of each patient.
Intervention Type
Biological
Intervention Name(s)
Nemvaleukin and Pembrolizumab Combination
Other Intervention Name(s)
Nemvaleukin alfa, ALKS 4230, Keytruda
Intervention Description
Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes and Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
Intervention Type
Biological
Intervention Name(s)
Pembrolizumab
Other Intervention Name(s)
Keytruda
Intervention Description
Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
Intervention Type
Biological
Intervention Name(s)
Nemvaleukin
Other Intervention Name(s)
Nemvaleukin alfa, ALKS 4230
Intervention Description
Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes
Intervention Type
Drug
Intervention Name(s)
Pegylated Liposomal Doxorubicin (PLD)
Other Intervention Name(s)
PLD- CAELYX, DOXIL, LIPODOX, Myocet
Intervention Description
40 mg/m2; Day 1 of 28-day cycles; IV infusion; 1 mg/min (Cycle 1); 60 min infusion (Cycles 2+)
Intervention Type
Drug
Intervention Name(s)
Paclitaxel
Other Intervention Name(s)
Nov-Onxol, Taxol, Onxol, Paclitaxel Novaplus
Intervention Description
80 mg/m2; Days 1, 8, 15, and 22 of 28-day cycles; IV infusion over 60 min
Intervention Type
Drug
Intervention Name(s)
Topotecan
Other Intervention Name(s)
Hycamtin, Potactasol
Intervention Description
4 mg/m2; Days 1, 8, and 15 of 28-day cycles; or 1.25 mg/m2, Days 1 through 5 of 21-day cycles; IV infusion over 30 min
Intervention Type
Drug
Intervention Name(s)
Gemcitabine
Other Intervention Name(s)
Gemzar, Infugem
Intervention Description
1,000 mg/m2; Days 1 and 8 of 21-day cycles; IV infusion over 30 min
Primary Outcome Measure Information:
Title
Progression-free survival (PFS) as assessed by Investigator
Time Frame
Up to 1 year
Secondary Outcome Measure Information:
Title
Objective response rate as assessed by Investigator
Time Frame
Up to 1 year
Title
Overall Survival Rate
Time Frame
Up to 3 years
Title
Disease Control Rate (DCR) as assessed by Investigator
Time Frame
Up to 1 year
Title
Duration of Response (DOR) as assessed by Investigator
Time Frame
Up to 1 year
Title
Time to Response (TTR) as assessed by Investigator
Time Frame
Up to 18-24 weeks
Title
Cancer antigen (CA)-125 response as defined by the Gynecologic Cancer InterGroup (GCIG)
Time Frame
Up to 1 year
Title
Incidence of treatment-emergent adverse events (TEAEs)
Time Frame
Up to 3 years

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is female and ≥18 years of age. Patient has histologically confirmed diagnosis of EOC (ie, high-grade serous, endometrioid of any grade, clear cell), fallopian tube cancer, or primary peritoneal cancer. Patient has platinum-resistant/refractory disease, defined as disease progression within 180 days following the last administered dose of platinum therapy beyond first-line setting (resistant) or lack of response or disease progression while receiving the most recent platinum-based therapy (refractory). Patient must have progressed radiographically on or after their most recent line of anticancer therapy. Patient must have received at least 1 prior line of systemic anticancer therapy in the platinum sensitive setting, and no more than 5 prior lines of systemic anticancer therapy in the platinum-resistant setting. Patient must have received at least 1 line of therapy containing bevacizumab. Patient has at least one measurable lesion that qualifies as a target lesion based on RECISTv1.1. Patient is willing to undergo a pre-treatment tumor biopsy or provide qualifying archival tumor tissue. Exclusion Criteria: Patient has primary platinum-refractory disease or primary platinum resistance, defined as disease progression during first-line platinum-based therapy (refractory) or disease progression <3 months after completion of first-line platinum-based therapy (resistant). Patient has histologically confirmed diagnosis of EOC with mucinous or carcinosarcoma subtype. Patient has nonepithelial tumor (eg, germline or stromal cell tumor) or ovarian tumor with low malignant potential (ie, borderline or low-grade serous tumor). Patient requires fluid drainage (eg, paracentesis, thoracentesis, pericardiocentesis) of ≥500 mL within 4 weeks of first dose of study drug. Patient has received prior IL-2-based or IL-15-based cytokine therapy; patient has had exposure, including intralesional, to IL-12 or analogs thereof. Patient has prior exposure to any anti-PD1/PD-L1 therapy.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Senior Direct, Global Clinical Services
Phone
888-235-8008 (US Only)
Email
clinicaltrials@alkermes.com
First Name & Middle Initial & Last Name or Official Title & Degree
Senior Direct, Global Clinical Services
Phone
1-571-599-2702 (Global)
Email
clinicaltrials@alkermes.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rita Dalal, MD
Organizational Affiliation
Alkermes, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Alkermes Investigator Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35216
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Anchorage
State/Province
Alaska
ZIP/Postal Code
99508
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigational Site
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85711
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Oxnard
State/Province
California
ZIP/Postal Code
93030
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32808
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34240
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40207
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70809
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48224
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Ypsilanti
State/Province
Michigan
ZIP/Postal Code
48197
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
East Brunswick
State/Province
New Jersey
ZIP/Postal Code
08816
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
New Brunswick
State/Province
New Jersey
ZIP/Postal Code
08901
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87131
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Albany
State/Province
New York
ZIP/Postal Code
12208
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Hawthorne
State/Province
New York
ZIP/Postal Code
105832
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Greenville
State/Province
North Carolina
ZIP/Postal Code
27834
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43215
Country
United States
Individual Site Status
Withdrawn
Facility Name
Alkermes Investigator Site
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43219
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Eugene
State/Province
Oregon
ZIP/Postal Code
97401
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Portland
State/Province
Oregon
ZIP/Postal Code
97213
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19014
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Sioux Falls
State/Province
South Dakota
ZIP/Postal Code
57105
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Austin
State/Province
Texas
ZIP/Postal Code
78731
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Bedford
State/Province
Texas
ZIP/Postal Code
76022
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76104
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22908
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Gainesville
State/Province
Virginia
ZIP/Postal Code
20155
Country
United States
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Adelaide
ZIP/Postal Code
5000
Country
Australia
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
East Melbourne
ZIP/Postal Code
3184
Country
Australia
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
South Brisbane
ZIP/Postal Code
4066
Country
Australia
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Graz
ZIP/Postal Code
8036
Country
Austria
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Innsbruck
ZIP/Postal Code
6020
Country
Austria
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Vienna
ZIP/Postal Code
1130
Country
Austria
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Brussels
ZIP/Postal Code
1000
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 4N2
Country
Canada
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8V 5C2
Country
Canada
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5W9
Country
Canada
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N 3M5
Country
Canada
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Sherbrooke
State/Province
Quebec
ZIP/Postal Code
J1H 5N4
Country
Canada
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Prague
ZIP/Postal Code
181 00
Country
Czechia
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Marseille
ZIP/Postal Code
13009
Country
France
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Berlin
ZIP/Postal Code
13353
Country
Germany
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Bonn
ZIP/Postal Code
53127
Country
Germany
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Kiel
ZIP/Postal Code
24105
Country
Germany
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Wiesbaden
ZIP/Postal Code
65199
Country
Germany
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Haifa
ZIP/Postal Code
34362
Country
Israel
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Aviano
ZIP/Postal Code
33081
Country
Italy
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Ponderano
ZIP/Postal Code
13875
Country
Italy
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Prato
ZIP/Postal Code
59100
Country
Italy
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Rome
ZIP/Postal Code
168
Country
Italy
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Torino
ZIP/Postal Code
10128
Country
Italy
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Treviso
ZIP/Postal Code
31100
Country
Italy
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Daegu
ZIP/Postal Code
42601
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Goyang-si
ZIP/Postal Code
10408
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Seoul
ZIP/Postal Code
5505
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Seoul
ZIP/Postal Code
6273
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Singapore
ZIP/Postal Code
329563
Country
Singapore
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Barcelona
ZIP/Postal Code
8908
Country
Spain
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Girona
ZIP/Postal Code
17007
Country
Spain
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Las Palmas De Gran Canaria
ZIP/Postal Code
35016
Country
Spain
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Murcia
ZIP/Postal Code
30120
Country
Spain
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Valencia
ZIP/Postal Code
46010
Country
Spain
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Vigo
ZIP/Postal Code
36312
Country
Spain
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Chang Hua
ZIP/Postal Code
500
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Taichung
ZIP/Postal Code
40447
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Taichung
ZIP/Postal Code
40705
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Tainan
ZIP/Postal Code
704
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator
City
Taipei
ZIP/Postal Code
10002
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Taipei
ZIP/Postal Code
11217
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Cambridge
ZIP/Postal Code
CB2 0QQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
London
ZIP/Postal Code
NW1 2PG
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Alkermes Investigator Site
City
Oxford
ZIP/Postal Code
OX3 9DU
Country
United Kingdom
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

We'll reach out to this number within 24 hrs